PYC Therapeutics Limited ( (AU:PYC)) has provided an announcement. PYC Therapeutics Limited has announced promising results from its ongoing Phase 1/2 clinical trials of VP-001, an investigational ...

The last three months have been tough on PYC Therapeutics Limited (ASX:PYC) shareholders, who have seen the share price decline a rather worrying 36%. But that doesn't change the fact that the returns ...

The considerable ownership by individual investors in PYC Therapeutics indicates that they collectively have a greater say in management and business strategy A total of 9 investors have a majority ...

PYC Therapeutics Limited has notified the market that it will issue 2,000,000 unlisted options as unquoted equity securities, effective 23 December 2025. The creation of this new class of unlisted ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics Limited has announced a significant breakthrough in treating Phelan-McDermid Syndrome (PMS), a rare neurodevelopmental ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has dosed its first patient in a clinical trial for its innovative drug candidate, PYC-001, which aims to treat Autosomal ...

PYC Therapeutics (ASX: PYC) presented its Q2 2025 investor webinar on May 30, outlining progress across its genetic medicine pipeline while facing continued market skepticism. The company’s stock ...

PYC Therapeutics (formerly Phylogica), is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell ...